Nonstimulant treatment of adult attention-deficit/hyperactivity disorder

Psychiatric Clinics of North America

Volumn 27, Issue 2, 2004, Pages 373-383

  Spencer, Thomas ^a,b   Biederman, Joseph ^a,b   Wilens, Timothy ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYL 5 (1 METHYL 2 PYRROLIDINYL)ISOXAZOLE; AMFEBUTAMONE; AMINE OXIDASE (FLAVIN CONTAINING); ATOMOXETINE; DESIPRAMINE; FLUOXETINE; IMIPRAMINE; METHYLPHENIDATE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOSE RESPONSE; DRUG EFFICACY; HUMAN; INSOMNIA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; CHOLINERGIC AGENTS; HUMANS; MONOAMINE OXIDASE INHIBITORS;

EID: 1842477052     PISSN: 0193953X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psc.2003.12.001     Document Type: Review

References (30)

1. Barkley R.A. A review of stimulant drug research with hyperactive children. J Child Psychol Psychiatry. 18:1977;137-165.
2. Gittelman R. Childhood disorders. Klein D., Quitkin F., Rifkin A., Gittelman R. Drug treatment of adult and child psychiatric disorders. 1980;576-756 Williams and Wilkins, Baltimore (MD).
3. Spencer T.J., Biederman J., Wilens T., Harding M., O'Donnell D., Griffin S. Pharmacotherapy of attention deficit hyperactivity disorder across the lifecycle: a literature review. J Am Acad Child Adolesc Psychiatry. 35:1996;409-432.
4. Quinn P.O., Rapoport J.L. One-year follow-up of hyperactive boys treated with imipramine or methylphenidate. Am J Psychiatry. 132:1975;241-245.
5. Biederman J., Baldessarini R.J., Wright V., Knee D., Harmatz J. A double-blind placebo controlled study of desipramine in the treatment of attention deficit disorder: I. Efficacy. J Am Acad Child Adolesc Psychiatry. 28:1989;777-784.
6. Wilens T.E., Biederman J.B., Mick E., Spencer T. A systematic assessment of tricyclic antidepressants in the treatment of adult attention-deficit/ hyperactivity disorder. J Nerv Ment Dis. 183:1995;48-50.
7. Wilens T.E., Biederman J., Prince J., Spencer T.J., Faraone S., Warburton R., et al. Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder. Am J Psychiatry. 153:1996;1147-1153.
8. Casat C.D., Pleasants D.Z., Schroeder D.H., Parler D.W. Bupropion in children with attention deficit disorder. Psychopharmacol Bull. 25:1989;198-201.
9. Casat C.D., Pleasants D.Z., Van Wyck Fleet J. A double-blind trial of bupropion in children with attention-deficit disorder. Psychopharmacol Bull. 23:1987;120-122.
10. Conners K., Casat C., Gualtieri T., Weller E., Reader M., Reiss A., et al. Bupropion hydrochloride in attention-deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry. 35:1996;1314-1321.
11. Barrickman L., Perry P., Allen A., Kuperman S., Arndt S., Herrmann K., et al. Bupropion versus methylphenidate in the treatment of attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 34:1995;649-657.
12. Wender P.H., Reimherr F.W. Bupropion treatment of attention-deficit hyperactivity disorder in adults. Am J Psychiatry. 147:1990;1018-1020.
13. Wilens T.E., Spencer T.J., Biederman J., Girard K., Doyle R., Prince J., et al. A controlled clinical trial of bupropion for attention-deficit/ hyperactivity disorder in adults. Am J Psychiatry. 158:2001;282-288.
14. Zametkin A., Rapoport J.L., Murphy D.L., Linnoila M., Ismond D. Treatment of hyperactive children with monoamine oxidase inhibitors: I. Clinical efficacy. Arch Gen Psychiatry. 42:1985;962-966.
15. Ernst M., Liebenauer L.L., Jons P.H., Tebeka D., Cohen R.M., Zametkin A.J. Selegiline in adults with attention deficit hyperactivity disorder: clinical efficacy and safety. Psychopharmacol Bull. 32:1996;327-334.
16. Trott G.E., Friese H.J., Menzel M., Nissen G. [Use of moclobemide in children with attention-deficit/hyperactivity disorder] Wirksamkeit und vertraglichkeit des selektiven MAO-A-inhibitors moclobemid bei kindern mit hyperkinetischem syndrom (both English and German versions). Jugendpsychiat. 19:1991;248-253.
17. Barrickman L., Noyes R., Kuperman S., Schumacher E., Verda M. Treatment of ADHD with fluoxetine: a preliminary trial. J Am Acad Child Adolesc Psychiatry. 30:1991;762-767.
18. NIMH Conference. Alternative pharmacology of ADHD; Washington, DC, 1996.
19. Hornig-Rohan M, Amsterdam J. Venlafaxine versus stimulant therapy in patients with dual diagnoses of ADHD and depression. Presented at the New Clinical Drug Evaluation Unit Program. Orlando (FL), June 10-14, 1995, Poster #92.
20. Findling R., Schwartz M., Flannery D., Manos M. Venlafaxine in adults with ADHD: an open trial. J Clin Psychiatry. 57:1996;184-189.
21. Adler L, Resnick S, Kunz M, Devinsky O. Open-label trial of venlafaxine in attention deficit disorder. Presented at the New Clinical Drug Evaluation Unit Program. Orlando, (FL), June 10-14, 1995.
22. Reimherr F, Hedges D, Strong R, Wender P. An open-trial of venlaxine in adult patients with attention deficit hyperactivity disorder. Presented at the New Clinical Drug Evaluation Unit Program. Orlando (FL), June 10-14, 1995.
23. Luh J., Pliszka S., Olvers R., Tatum R. An open trial of venlafaxine in the treatment of attention-deficit/hyperactivity disorder: a pilot study. 1996;The University of Texas Health Science Center at San Antonio, San Antonio (TX).
24. Spencer T., Biederman J., Wilens T., Prince J., Hatch M., Jones J., et al. Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry. 155:1998;693-695.
25. Spencer T., Biederman J., Heiligenstein J., et al. An open-label, dose-ranging study of atomoxetine in children with attention-deficit/ hyperactivity disorder. J Child Adolesc Psychopharmacol. 11:2001;251-265.
26. Spencer T., Heiligenstein J., Biederman J., et al. Atomoxetine in children with ADHD: results from two randomized, placebo-controlled studies. J Clin Psychiatry. 63:2002;1140-1147.
27. Michelson D., Faries D., Wernicke J., Kelsey D., Kendrick K., Sallee F., et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics. 108:2001;E83.
28. Kratochvil C.J., Bohac D., Harrington M., Baker N., May D., Burke W.J. An open-label trial of tomoxetine in pediatric attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 11:2001;167-170.
29. Michelson D., Adler L., Spencer T., Reimherr F., West S., Allen A., et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry. 53:2003;112-120.
30. Wilens T.E., Biederman J., Spencer T.J., Bostic J., Prince J., Monuteaux M., et al. A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention-deficit/hyperactivity disorder. Am J Psychiatry. 156:1999;1931-1937.